October 22, 2018 / 5:43 AM / a month ago

BRIEF-Ipsen Presents Real-World Pancreatic Cancer Data On ONIVYDE

Oct 22 (Reuters) - IPSEN SA:

* REPORTED ON SUNDAY REAL-WORLD PANCREATIC CANCER DATA ON ONIVYDE

* PATIENTS IN REAL-WORLD SETTING EXPERIENCED SIMILAR DOSING PATTERNS AS SEEN IN PIVOTAL PHASE 3 NAPOLI-1 CLINICAL TRIAL

* RESULTS ARE GENERALLY CONSISTENT WITH NAPOLI-1 TRIAL, HOWEVER, DOSE MODIFICATIONS IN REAL-WORLD ANALYSIS WERE LOWER (27.2% VS 45% IN NAPOLI-1)

* MOST COMMON ADVERSE REACTIONS IN NAPOLI-1 (≥20%) WERE DIARRHEA (59%), FATIGUE/ASTHENIA (56%), VOMITING (52%), NAUSEA (51%), DECREASED APPETITE (44%), STOMATITIS (32%), AND PYREXIA (23%)

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below